Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.72 |
| ▸ | BCL2 | P10415 | 15/20 | 0.46 |
| ▸ | BAD | Q92934 | 3/20 | 0.45 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424527 | 1.00 | BCL2L1 (0.72) | BCL2L1BCL2BADBCL2L11CYP2C9 | |
| SCHEMBL554039 | 1.00 | BCL2L1 (0.72) | BCL2L1BCL2BADBCL2L11CYP2C9 | |
| SCHEMBL554106 | 0.91 | BCL2L1 (0.59) | BCL2L1BCL2BADBCL2L11CYP2C9 | |
| SCHEMBL554105 | 0.91 | BCL2L1 (0.59) | BCL2L1BCL2BADBCL2L11CYP2C9 | |
| SCHEMBL29424532 | 0.91 | BCL2L1 (0.59) | BCL2L1BCL2BADBCL2L11CYP2C9 | |
| SCHEMBL554894 | 0.88 | BCL2L1 (0.67) | BCL2L1BCL2BADBCL2L11CYP2C9 | |
| SCHEMBL554895 | 0.88 | BCL2L1 (0.67) | BCL2L1BCL2BADBCL2L11CYP2C9 | |
| SCHEMBL555011 | 0.88 | BCL2L1 (0.67) | BCL2L1BCL2BADBCL2L11CYP2C9 | |
| SCHEMBL554650 | 0.87 | BCL2L1 (0.68) | BCL2L1BCL2BAD | |
| SCHEMBL554649 | 0.87 | BCL2L1 (0.68) | BCL2L1BCL2BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2024-06-06 | — | — | US | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11590126-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220273666-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | RECURIUM IP HOLDINGS, LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220226314-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2022-07-21 | — | — | US | disclosed |
| US-11318134-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2021007303-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | RECURIUM IP HOLDINGS, LLC (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20200338071-A1 | BENZAMIDE COMPOUNDS | ZENO MANAGEMENT, INC. | 2020-10-29 | — | — | US | disclosed |
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885BCL2 69/4885BAD 55/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885BCL2 69/4885BAD 55/4885 |
| US-11590126-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885BCL2 69/4885BAD 55/4885 |
| US-11318134-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885BCL2 69/4885BAD 55/4885 |
| US-20220273666-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | BCL2, BCL2L2, BCL2L1 | BCL2L1 3/4885BCL2 1/4885BAD 19/4885 |
| US-20220226314-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885BCL2 69/4885BAD 55/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BAD 13/4885 |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885BCL2 69/4885BAD 55/4885 |
| US-20200338071-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885BCL2 69/4885BAD 55/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BAD 13/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BAD 13/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | BCL2L1 6/4885BCL2 1/4885BAD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.